{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:30:17Z","timestamp":1787499017924,"version":"build-2736575974"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Triple negative breast cancer (TNBC) is a breast cancer with a poor prognosis, marked by the absence of estrogen (ER) and progesterone (PR) receptors as well as human epidermal growth factor receptor (HER2) expression. Although TNBC is characterized by a high recurrence rate and poorer survival, it is more sensitive to chemotherapy compared to other breast cancer subtypes. The use of targeted immunotherapy approaches has been brought to the agenda for the treatment of both early and advanced TNBC, as TNBCs are immunogenic active tumors. In systemic therapy, addition of immune checkpoint inhibitors to cytotoxic chemotherapy is used as part of the neoadjuvant treatment approach. Pembrolizumab is a monoclonal antibody that blocks the interaction between the programmed death-ligand 1 (PD-L1) receptor on T cells and the PD-L1 and PD-L2 ligands on tumor cells. It has been shown to be effective in TNBC, melanoma, lung cancer and other advanced solid tumors and hematologic malignancies. Several skin-related side effects have been documented, such as pruritus, maculopapular rashes, vitiligo, lichenoid skin reactions, psoriasis, and, in rare cases, severe and potentially life-threatening conditions. We report a rare case of pembrolizumab-associated lichen planus in a 43-year-old woman who received pembrolizumab for neoadjuvant treatment of TNBC.<\/jats:p>","DOI":"10.3389\/fonc.2025.1726097","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T05:14:11Z","timestamp":1767762851000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Pembrolizumab associated lichen planus in early stage triple negative breast cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Ozge","family":"Buyukahisha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Ozcelik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Baycelebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asena","family":"Cakir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent","family":"Cetin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1134569","article-title":"Cutaneous adverse reactions of immunotherapy in patients with advanced melanoma","volume":"15","author":"Nikolaou","year":"2023","journal-title":"Cancers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/1742-6723.12718","article-title":"Acute management of autoimmune toxicity in cancer patients on immunotherapy: common toxicities and the approach for the emergency physician","volume":"29","author":"Lomax","year":"2017","journal-title":"Emergency Med Australasia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.157","article-title":"Immune checkpoint inhibitor\u2013related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000300","article-title":"Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies","volume":"28","author":"Sibaud","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.068","article-title":"An effective game-based learning intervention for improving melanoma recognition","volume":"79","author":"Sharma","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0073","article-title":"Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC","volume":"6","author":"Santini","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Schneider","year":"2018","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti\u2013programmed cell death 1 and anti\u2013programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features","volume":"83","author":"Ellis","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18879","article-title":"Cutaneous lichenoid drug eruptions: A narrative review evaluating demographics, clinical features and culprit medications","volume":"37","author":"Maul","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2023-0081","article-title":"Lichenoid dermatitis following PD-1 inhibitor-induced toxic epidermal necrolysis: a case report and literature review","volume":"15","author":"Zhang","year":"2023","journal-title":"Immunotherapy"},{"key":"B14","article-title":"Immune-mediated dermatologic toxicities in cancer patients treated with checkpoint inhibitors","volume":"24","author":"Rosenberg","year":"2019","journal-title":"Oncologist"},{"key":"B15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"Collins","year":"2017","journal-title":"Curr Problems Cancer"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"American journal of clinical dermatology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15246","article-title":"Immune-related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: a single-center retrospective study in Japan","volume":"47","author":"Otsuka","year":"2020","journal-title":"J Dermatol"},{"key":"B20","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities","volume":"4","author":"Villadolid","year":"2015","journal-title":"Trans Lung Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0133","article-title":"Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors","volume":"22","author":"Judd","year":"2017","journal-title":"Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non\u2013small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2022.12.007","article-title":"Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors","volume":"4","author":"Nunez","year":"2023","journal-title":"Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jds.2024.10.024","article-title":"Pembrolizumab-induced oral lichen planus pemphigoides with mucous membrane pemphigoid preceding lichen planus","volume":"20","author":"Maeda","year":"2024","journal-title":"J Dental Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.15570\/actaapa.2016.11","article-title":"Acta Dermatovenerologica Alpina, Pannonica etAdriatica accepted for coverage in Thomson reuters\u2019 Emerging Sources Citation Index (ESCI)","volume":"25","author":"Poljak","year":"2016","journal-title":"Acta Dermatovenerol Alpina Pannonica Adriatica"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1159\/000519486","article-title":"Pembrolizumab-induced lichen planus on the scalp of a patient with non-small-cell lung carcinoma","volume":"13","author":"Yamashita","year":"2021","journal-title":"Case Rep Dermatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13768","article-title":"Pembrolizumab-induced lichenoid dermatitis in a patient with metastatic cancer of unknown primary","volume":"13","author":"Sethi","year":"2021","journal-title":"Cureus"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.31454","article-title":"Pembrolizumab-induced lichen planus in a patient with non-small-cell lung carcinoma (NSCLC) that correlates to therapeutic response","volume":"14","author":"Sehbai","year":"2022","journal-title":"Cureus"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.43402","article-title":"Pembrolizumab-induced eruptive keratoacanthomas and lichen planus in a lung cancer patient","volume":"15","author":"Tembunde","year":"2023","journal-title":"Cureus"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/dermatopathology10030033","article-title":"Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic adrenocortical cancer: a case report and literature review","volume":"10","author":"Madan","year":"2023","journal-title":"Dermatopathology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jdcr.2023.05.004","article-title":"Pembrolizumab-induced lichenoid dermatitis treated with dupilumab","volume":"37","author":"Park","year":"2023","journal-title":"JAAD Case Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.idoj_377_22","article-title":"Pembrolizumab-induced lichen planus: A rare immune-related adverse side effect","volume":"14","author":"Bansal","year":"2023","journal-title":"Indian Dermatol Online J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.03.007","article-title":"Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic Merkel cell carcinoma","volume":"6","author":"Kwon","year":"2020","journal-title":"JAAD Case Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/cup.14299","article-title":"Lichen-planus-pemphigoides-like reaction to PD-1 checkpoint blockade","volume":"49","author":"Wat","year":"2022","journal-title":"J Cutaneous Pathol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr3750","article-title":"Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors and cytotoxic T-lymphocyte-associated protein-4 inhibitors): results of a retrospective study","volume":"11","author":"Bajwa","year":"2019","journal-title":"J Clin Med Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1726097\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T05:14:13Z","timestamp":1767762853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1726097\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":37,"alternative-id":["10.3389\/fonc.2025.1726097"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1726097","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"article-number":"1726097"}}